---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-017504"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T15:04:01.616033+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jury awards Puma/Wyeth $107.5M in Tagrisso patent infringement case vs AstraZeneca

## Summary
- Jury found '314 and '162 patents infringed and not invalid; damages $107.5M for past acts.
- Puma was dismissed as plaintiff but retains contractual right to recover damages under Pfizer license.
- Bench trial on equitable defenses (unclean hands, patent misuse) set for June 17-18, 20, 2024.
- Further proceedings will determine ongoing royalty rate through patent term.

## SEC filing metadata
- accession: 0001437749-24-017504
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774924017504/0001437749-24-017504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774924017504/pbyi20240517_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-017504
- JSON: https://secwatch.observer/filing/0001437749-24-017504.json
- Plain text: https://secwatch.observer/filing/0001437749-24-017504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.